Stockscreener 앱 받기
18.75
2.14%
-0.41
시간 외 거래:
19.51
0.76
+4.05%
전일 마감가:
$19.16
열려 있는:
$19.06
하루 거래량:
3.88M
Relative Volume:
1.02
시가총액:
$13.93B
수익:
$220.00K
순이익/손실:
$-746.08M
주가수익비율:
-18.61
EPS:
-1.0074
순현금흐름:
$-211.81M
1주 성능:
-14.66%
1개월 성능:
-2.09%
6개월 성능:
-43.58%
1년 성능:
-6.39%
1일 변동 폭
$18.46
$19.20
1주일 범위
$18.08
$22.34
52주 변동 폭
$15.55
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
명칭
Summit Therapeutics Inc
전화
305-203-2034
주소
601 BRICKELL KEY DRIVE, MIAMI
SMMT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
18.75 | 13.95B | 220.00K | -746.08M | -211.81M | -1.0074 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.63 | 109.29B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.00 | 62.13B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
575.69 | 61.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.18 | 51.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
310.03 | 34.68B | 4.56B | -176.77M | 225.30M | -1.7177 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-17 | 개시 | Barclays | Underweight |
| 2025-09-04 | 개시 | Guggenheim | Buy |
| 2025-08-19 | 개시 | Piper Sandler | Neutral |
| 2025-07-01 | 개시 | UBS | Buy |
| 2025-06-11 | 개시 | Leerink Partners | Underperform |
| 2025-03-26 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-03-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-03-12 | 개시 | Evercore ISI | Outperform |
| 2025-02-28 | 개시 | Goldman | Buy |
| 2025-01-08 | 개시 | Truist | Buy |
| 2024-12-11 | 개시 | Wells Fargo | Overweight |
| 2024-12-06 | 개시 | Jefferies | Buy |
| 2024-11-04 | 개시 | JMP Securities | Mkt Outperform |
| 2024-09-27 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-08-12 | 개시 | H.C. Wainwright | Buy |
| 2024-05-07 | 개시 | Citigroup | Buy |
| 2024-03-26 | 개시 | Stifel | Buy |
| 2018-06-28 | 다운그레이드 | Janney | Buy → Neutral |
| 2018-05-02 | 개시 | Janney | Buy |
| 2018-04-12 | 재확인 | Needham | Buy |
| 2018-02-13 | 개시 | BTIG Research | Buy |
| 2018-01-04 | 개시 | SunTrust | Buy |
| 2017-12-01 | 재개 | H.C. Wainwright | Buy |
| 2016-11-16 | 재확인 | RBC Capital Mkts | Outperform |
| 2016-10-05 | 재확인 | Needham | Buy |
| 2016-09-16 | 개시 | H.C. Wainwright | Buy |
| 2015-03-30 | 개시 | Needham | Buy |
| 2015-03-30 | 개시 | Oppenheimer | Outperform |
모두보기
Summit Therapeutics Inc 주식(SMMT)의 최신 뉴스
Biotech Alert: Searches spiking for these stocks today - TipRanks
Applying sector rotation models to Summit Therapeutics Inc.Market Trend Report & High Win Rate Trade Alerts - newser.com
Is Summit Therapeutics Inc. showing signs of accumulationQuarterly Trade Report & Low Volatility Stock Recommendations - newser.com
Analyzing Summit Therapeutics Inc. with risk reward ratio chartsPortfolio Performance Report & AI Forecasted Entry/Exit Points - newser.com
Summit Therapeutics raises $500 million - The Pharma Letter
News impact scoring models applied to Summit Therapeutics Inc.Volume Spike & Safe Capital Growth Tips - newser.com
Can Summit Therapeutics Inc. hit a new high this monthEarnings Performance Report & Risk Controlled Stock Pick Alerts - newser.com
Should you hold or exit Summit Therapeutics Inc. nowTrade Exit Summary & Expert Curated Trade Ideas - newser.com
Is Summit Therapeutics Inc. stock reversal real or fakeJuly 2025 Trends & Real-Time Chart Breakout Alerts - newser.com
Summit Therapeutics raises $500M in private placement - MSN
Guggenheim Reiterates Summit Therapeutics (SMMT) Buy Recommendation - Nasdaq
Understanding the Setup: (SMMT) and Scalable Risk - news.stocktradersdaily.com
Summit Therapeutics (SMMT) Rating Reaffirmed at "Buy" by Guggenh - GuruFocus
Summit Therapeutics (SMMT) Secures $500M in Stock Placement - GuruFocus
Summit Therapeutics Raises $500M in Private Placement - TipRanks
Summit Therapeutics raises $500 million in private placement - MarketScreener
Summit Therapeutics Raises $500 Million in Private Placement - Business Wire
Assessing Summit Therapeutics After Volatile Price Moves and Late-Stage Clinical Updates in 2025 - Yahoo Finance
Summit Therapeutics Inc. stock momentum explainedWeekly Profit Report & Expert Curated Trade Setup Alerts - newser.com
Barclays Maintains Summit Therapeutics (SMMT) Underweight Recommendation - Nasdaq
SA analyst upgrades/downgrades: TSLA, MSFT, AAPL, SMMT - Seeking Alpha
SMMT's Q3 Loss Wider Than Expected, Stock Down on Study Amendments - TradingView
SMMT: Barclays Raises Price Target to $16 While Maintaining "Und - GuruFocus
HC Wainwright & Co. Maintains Summit Therapeutics (SMMT) Buy Recommendation - Nasdaq
SMMT: HC Wainwright & Co. Lowers Price Target but Maintains Buy - GuruFocus
Summit Therapeutics (SMMT) Expands its Phase 3 Trials for Ivonescimab - Insider Monkey
13 Best Growth Stocks Under $25 to Buy Right Now - Insider Monkey
Summit to seek US approval for ivonescimab in lung cancer despite survival miss - The Pharma Letter
Decoding Summit Therapeutics Inc (SMMT): A Strategic SWOT Insight - GuruFocus
Summit Therapeutics Advances Ivonescimab Development Amid Financial Growth - TipRanks
How to use Fibonacci retracement on Summit Therapeutics Inc.Quarterly Investment Review & Long-Term Safe Return Strategies - newser.com
Automated trading signals detected on Summit Therapeutics Inc.Trade Volume Report & Weekly Stock Breakout Alerts - newser.com
Summit Therapeutics Inc (SMMT) Q3 2025 Earnings Call Highlights: Promising Clinical ... By GuruFocus - Investing.com Canada
Citigroup Maintains Summit Therapeutics (SMMT) Buy Recommendation - Nasdaq
Earnings call transcript: Summit Therapeutics Q3 2025 reports narrower loss, stock drops - Investing.com Nigeria
Summit Therapeutics stock price target lowered to $42 by Jefferies - Investing.com Canada
Summit Therapeutics Inc (SMMT) Q3 2025 Earnings Call Highlights: Promising Clinical ... - Yahoo Finance
Summit Therapeutics Launches New Phase III Study - TipRanks
Summit’s Bold BLA Without Stat-Sig OS: Why I Step Back To Hold (NASDAQ:SMMT) - Seeking Alpha
Summit Therapeutics Inc (SMMT) Q3 2025 Earnings Call Highlights: - GuruFocus
JMP Securities Reiterates Summit Therapeutics (SMMT) Market Outperform Recommendation - Nasdaq
Summit Seeks Cancer Drug’s Approval Despite US Regulator Warning - Bloomberg.com
Summit Therapeutics Q3 2025 Earnings Call Transcript - MarketBeat
Citigroup Raises Price Target for Summit Therapeutics (SMMT) to $40 | SMMT Stock News - GuruFocus
Summit Therapeutics (SMMT) Shares Dip on Q3 Earnings Miss - GuruFocus
Is it time to cut losses on Summit Therapeutics Inc.Treasury Yields & Daily Chart Pattern Signal Reports - newser.com
SMMT: JMP Securities Reiterates "Market Outperform" Rating Today | SMMT Stock News - GuruFocus
Earnings call transcript: Summit Therapeutics Q3 2025 reports narrower loss, stock drops By Investing.com - Investing.com South Africa
Summit Therapeutics Q3 2025 slides: positive HARMONI-6 data fails to lift stock - Investing.com
What's Going On With Summit Therapeutics Stock On Monday? - Benzinga
Summit Therapeutics stock rating reiterated by Cantor Fitzgerald By Investing.com - Investing.com South Africa
Summit Therapeutics Inc (SMMT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Summit Therapeutics Inc 주식 (SMMT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Zanganeh Mahkam | Co-Chief Executive Officer |
Sep 11 '25 |
Buy |
18.07 |
5,000 |
90,350 |
556,093,090 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Sep 10 '25 |
Buy |
17.68 |
333,394 |
5,894,406 |
556,088,090 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Sep 11 '25 |
Buy |
18.07 |
5,000 |
90,350 |
556,093,090 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
May 30 '25 |
Option Exercise |
2.64 |
74,545 |
196,799 |
555,754,696 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
May 30 '25 |
Option Exercise |
2.64 |
74,545 |
196,799 |
555,754,696 |
0.03%
0.17%
자본화:
|
볼륨(24시간):